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Abstract
Introduction: Natural killer (NK) and natural killer T (NKT) cells provide a first line of defense against infection.
However, these cells have not yet been examined in patients with Lyme arthritis, a late disease manifestation. Lyme
arthritis usually resolves with antibiotic treatment. However, some patients have persistent arthritis after spirochetal
killing, which may result from excessive inflammation, immune dysregulation and infection-induced autoimmunity.
Methods: We determined the frequencies and phenotypes of NK cells and invariant NKT (iNKT) cells in paired
peripheral blood (PB) and synovial fluid (SF) samples from eight patients with antibiotic-responsive arthritis and
fifteen patients with antibiotic-refractory arthritis using flow cytometry and cytokine analyses.
Results: In antibiotic-responsive patients, who were seen during active infection, high frequencies of CD56bright
NK cells were found in SF, the inflammatory site, compared with PB (P <0.001); at both sites, a high percentage of
cells expressed the activation receptor NKG2D and the chaperone CD94, a low percentage expressed inhibitory
killer immunoglobulin-like receptors (KIR), and a high percentage produced IFN-γ. In antibiotic-refractory patients,
who were usually evaluated near the conclusion of antibiotics when few if any live spirochetes remained, the
phenotype of CD56bright cells in SF was similar to that in patients with antibiotic-responsive arthritis, but the
frequency of these cells was significantly less (P =0.05), and the frequencies of CD56dim NK cells tended to be
higher. However, unlike typical NKdim cells, these cells produced large amounts of IFN-γ, suggesting that they were
not serving a cytotoxic function. Lastly, iNKT cell frequencies in the SF of antibiotic-responsive patients were
significantly greater compared with that of antibiotic-refractory patients where these cells were often absent
(P= 0.003).
Conclusions: In patients with antibiotic-responsive arthritis, the high percentage of activated, IFN-γ-producing
CD56bright NK cells in SF and the presence of iNKT cells suggest that these cells still have a role in spirochetal
killing late in the illness. In patients with antibiotic-refractory arthritis, the frequencies of IFN-γ-producing CD56bright
and CD56dim NK cells remained high in SF, even after spirochetal killing, suggesting that these cells contribute to
excessive inflammation and immune dysregulation in joints, and iNKT cells, which may have immunomodulatory
effects, were often absent.
Introduction
Lyme disease, which occurs in North America, Europe
and Asia, is caused by infection with tick-borne spiro-
chete Borrelia burgdorferi [1]. Lyme arthritis, a late
manifestation of the disorder [2], can usually be treated
successfully with one month of oral or intravenous (IV)
antibiotics, termed antibiotic-responsive arthritis [3,4].
However, in a small percentage of patients, proliferative
synovitis persists for months to several years despite two
to three months of oral and IV antibiotics, called
antibiotic-refractory arthritis [5]. This complication has
been noted primarily in patients with Lyme arthritis in
the northeastern United States.
Antibiotic-refractory Lyme arthritis is more frequent
in patients infected with highly inflammatory RNA inter-
genic spacer type 1 (RST1) strains of B. burgdorferi [6],
which account for 30 to 50% of the infections in the
northeastern U.S. [7,8]. However, culture and PCR re-
sults for B. burgdorferi in synovial tissue obtained at
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uniformly negative [9], suggesting that refractory arth-
ritis does not result from persistent infection. Rather,
in genetically susceptible individuals, particularly those
with a Toll-like receptor 1 (TLR1) polymorphism [10]
and/or certain HLA-DR alleles [11], excessive joint in-
flammation associated with certain B. burgdorferi strains
[6], B. burgdorferi proteins [12] or spirochetal antigens
adherent to cartilage surfaces [13], may lead to immune
dysregulation of CD4+ T cell subsets [14,15] and infec-
tion-induced autoimmunity [16], resulting in persistent
joint inflammation after spirochetal killing with anti-
biotic therapy.
T cells, B cells, and natural killer (NK) cells make up
the three lineages of lymphocytes. NK cells, which com-
prise 5 to 12% of peripheral blood (PB), provide a first
line of defense against infection, and they can sponta-
neously kill virally infected or malignant cells [17,18].
More recently, it has been shown that NK cells also have
immunoregulatory properties that influence the adaptive
immune response, and maladaption of these responses
may lead to autoimmunity [19,20]. The functional acti-
vity of NK cells is regulated through their repertoire of
activating and inhibitory receptors that recognize ligands
on the surface of cells.
NK cells can be subtyped based upon their expression
levels of CD56, a homophilic neural cell adhesion mole-
cule. The majority of NK cells in PB are CD56dim cells,
whereas CD56bright cells are typically increased at sites
of inflammation [18]. CD56bright NK cells usually have
low or negligible expression of the FcγRIII receptor
(CD16low/-); they are typically noncytotoxic, and they
generally express high levels of cytokines [19]. In con-
trast, CD56dim NK cells, which are thought to be de-
rived from CD56bright cells, are usually CD16high; they
are typically cytotoxic, and they express low levels of
cytokines [21]. However, depending upon the inflam-
matory milieu, the phenotype and function of either NK
cell subtype can be changed leading to altered effector
or regulatory functions [18].
Natural killer T (NKT) cells, a subgroup of T cells
comprising about 0.2% of lymphocytes, express surface
antigens associated with both adaptive (T cell receptor)
and innate (NK receptors) immunity [22]. NKT cells,
which are potent producers of cytokines, foster protec-
tive immunity to microbes and tumor cells, but also help
maintain tolerance to self. In humans, NKT cells re-
cognize lipids presented by a family of nonclassical
MHC class I molecules called CD1a, b, c, d, or e [23].
Because of this variability, NKT cells are classified based
upon their recognition of specific CD1 molecules and
expression of specific α and β chains of the T cell recep-
tor. The most studied NKT cell subtype is invariant
NKT (iNKT) cells, the only type found in mice. In
humans, the iNKT cell receptor expresses the Vα24-Jα18
α chain and the Vβ11 β chain [24].
In Lyme disease, NK and NKT cells have been assessed
in tissue culture [25], in murine models of B. burgdorferi
infection [25-27], and in patients with erythema migrans
(EM), an early disease manifestation [28]. However, it is
not yet known whether NK or NKTcells play a role late in
the illness in patients with Lyme arthritis. We report here
that patients with antibiotic-responsive arthritis had high
percentages of activated IFN-γ-producing CD56bright NK
cells in synovial fluid (SF) and increased frequencies of
iNKT cells there, suggesting that these cells still have a
role in spirochetal killing late in the illness. However, in
patients with antibiotic-refractory arthritis, the frequencies
of IFN-γ-producing CD56bright and CD56dim NK cells
remained high in SF after spirochetal killing, suggesting
that these cells contribute to excessive inflammation and
immune dysregulation in joints, and iNKT cells, which
may have immunomodulatory effects, were often absent.
Methods
Study population
Paired samples of PB and SF from twenty-three patients
with Lyme arthritis, eight with antibiotic-responsive arth-
ritis and fifteen with antibiotic-refractory arthritis, were
available for most experiments except where indicated.
The Human Investigation Committee at Massachusetts
General Hospital (MGH) approved the study, entitled
‘Immunity in Lyme arthritis’, and all patients (or the pa-
rents of patients who were minors) provided written in-
formed consent. All patients met the Center for Disease
Control and Prevention criteria for the diagnosis of Lyme
disease [29], and received antibiotic therapy according
to the guidelines of the Infectious Diseases Society of
America [30]. For comparison, PB was also obtained from
four healthy control subjects.
As in the past [5], antibiotic-responsive arthritis was
defined as resolution of arthritis within three months
after four to eight weeks of oral antibiotics or ≤4 weeks
of IV antibiotics. Antibiotic-refractory arthritis was de-
fined as persistent joint swelling for >3 months after ≥8
weeks of oral antibiotics and ≥4 weeks of IV antibiotics.
PCR and antibody testing for B. burgdorferi were deter-
mined as previously described [9], and the total white
cell counts and the percentages of polymorphonuclear
leukocytes in SF were measured in the MGH clinical
laboratories.
Surface staining of cells and flow cytometry
For enumeration of the various immune cell popu-
lations, PB and SF cells were thawed and washed in
phosphate-buffered saline (PBS) in the presence of 1%
fetal calf serum and incubated for 30 minutes at 4°C.
Lymphocytes were identified by their forward and side
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upon CD56 expression (PerCp Cy5.5 anti-human CD56)
within the gated CD3-negative (FITC anti-human CD3)
lymphocyte population. To discriminate between the
CD56bright (high intensity) and CD56dim (low intensity)
NK cell subpopulations, two regions were established
within the CD3-CD56+ NK cell gate in accordance with
previous reports [31,32]. Invariant NKT cells were distin-
guished based upon CD56 and Vα24 expression within
the CD3-positive lymphocyte gate. All samples for this
panel were analyzed on FACSCalibur using CellQuest
software (Becton Dickinson, Franklin Lakes, NJ, USA).
To determine inhibitory and activating receptors expres-
sion on NK cells, the monoclonal antibody (mAb) panel
consisted of phycoerythrin (PE) anti-human killer im-
munoglobulin-like receptors (KIRs) (CD158e1 KIR3DL1
(DX9)) and CD158b KIR2DL2/2DL3 (DX27), PerCp
Cy5.5 anti-human CD56, Pacific Blue anti-human CD3,
Alexa Fluor™ 700 anti-human CD16, Alexa Fluor™ 647
anti-human CD94 (DX22), and PE/Cy7 anti-human
CD314 (NKG2D). The samples were analyzed using a
four-laser LSRII (Becton Dickinson) and FlowJo soft-
ware (TreeStar, Ashland, OR, USA).
B. burgdorferi culture and enumeration
Al o w - p a s s a g eB. burgdorferi RST1 strain (EM70), a strain
type with greater inflammatory potential than other strains
[33], was cultured in Barbour-Stoenner-Kelly (BSK)
medium containing 6% rabbit serum (Sigma-Aldrich, St
Louis, MO, USA) at 37°C with 5% CO2. Spirochetes were
harvested at late-log phase (0.5 to 2 × 10
9)b yc e n t r i f u g a -
tion at 14,000 rpm, washed twice with PBS, and resus-
pended in RPMI medium. The number of organisms was
enumerated by dark-field microscopy using a Petroff-
Hausser counting chamber.
Cell stimulation and intracellular staining for cytokines
For cytokine analyses, cells were thawed and resuspended
in culture media (RPMI 1640, supplemented with 10%
fetal calf serum, 1% penicillin/streptomycin and 2 mM
L-glutamine); they were counted and plated in 96-well
round bottom plate at a concentration of 2 × 10
5 per well.
Cells were stimulated with B. burgdorferi at a MOI of 25:1
for 24 h at 37°C and 5% CO2. As controls, cells were sti-
mulated either with phorbol 12-myristate-13-acetate
(10 ng/ml) and ionomycin (0.5 μg/ml) (positive control)
or media alone (negative control) (data not shown). To
inhibit cytokine secretion, 2 μM monensin (GolgiStop; BD
Biosciences Pharmingen, San Diego, CA, USA) was added
for the last 6 h.
Cells were harvested and stained for the surface
marker CD56 and CD3 at 4°C for 20 min. After incuba-
tion, the cells were washed twice with PBS and intracel-
lular staining was performed using a Cytofix/Cytoperm™
kit (BD Biosciences) following the manufacturer’s
instructions. Cells were stained with Alexa Fluor™ 488
anti-human IFN-γ, PE-Cy7 anti-human TNF-α and
PerCp Cy5.5 anti-human IL-4 mAbs, fixed with 4% para-
formaldehyde and analyzed by flow cytometry.
Statistical analysis
The distribution of values between groups was com-
pared by Mann-Whitney rank sum test. The Prism sta-
tistical program (GraphPad Software, San Diego, CA,
USA) was used for all analyses. All P values were two-
tailed, and P values <0.05 were considered statistically
significant.
Results
Clinical characteristics of patients
The demographic and clinical characteristics of the
twenty-three study patients with Lyme arthritis and four
healthy control subjects are shown in Table 1. Among
the eight patients with antibiotic-responsive arthritis, SF
samples were usually obtained prior to or soon after the
initiation of antibiotic treatment when the infection was
still active. At that time, PCR results for B. burgdorferi
DNA in SF were positive in all patients, and the median
white cell count in SF was 25,750 cells/mm
3. These pa-
tients received oral doxycycline for one or two months,
in two cases followed by IV ceftriaxone for one month,
and by definition, their arthritis resolved within three
months after the start of antibiotics.
In contrast, the fifteen patients with antibiotic-refrac-
tory arthritis included one who was referred to our clinic
before antibiotic therapy, five who were referred after
one to two months of oral antibiotics, and nine who
were referred at the completion of two months of oral
antibiotics and one month of IV antibiotic treatment. By
definition, all fifteen patients received one to two
months of oral antibiotics and one month of IV anti-
biotics, but their arthritis did not resolve within three
months after the start of this therapy. The PB and SF
samples from patients with refractory arthritis were ob-
tained when the patients were first seen in our clinic, a
median duration of four months (range zero to eighteen
months) after the start of antibiotics (Table 1). On the
sample date, only five of the fifteen patients had positive
PCR results for B. burgdorferi DNA in SF, and the me-
dian total white cell count in SF was 12,150 cells/mm
3.
These values, which were usually obtained when few, if
any, live spirochetes remained, were significantly less
than those in patients with antibiotic-responsive arthritis
(Table 1). However, in both the refractory and responsive
groups, most of the white cells in SF were polymorpho-
nuclear leukocytes (median value, 88% versus 79%).
After the completion of antibiotic therapy, the patients
with antibiotic-refractory arthritis were treated with
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lowed in one case by arthroscopic synovectomy. Their
arthritis resolved a median duration of ten months (range,
four to twenty months) after the start of antibiotics.
Frequencies of NK cell subsets
Although the total white cell counts in SF were signifi-
cantly greater in patients with antibiotic-responsive arth-
ritis than in those with antibiotic-refractory arthritis, the
frequencies of mononuclear cells at that site were similar
in the two patient groups (Table 1). The gating strategy to
distinguish the various lymphocyte populations within the
pool of mononuclear cells is shown in Figure 1a. When
gated on lymphocytes, PB from healthy control subjects
and PB and SF from patients with antibiotic-responsive or
antibiotic-refractory arthritis had similar percentages of
CD3+ T cells, CD3-CD56+ NK cells, and CD3-CD56-
cells, which were primarily B cells (Figure 1b).
When NK cells were subtyped based on CD56 expres-
sion levels, the median frequencies of CD56bright NK
cells were significantly greater in SF than PB in both
patient groups (P ≤0.001). However, their frequencies
were significantly greater in the SF of patients with
antibiotic-responsive arthritis compared with those with
antibiotic-refractory arthritis (median values, 27% versus
13%, P =0.05) (Figure 1c). In contrast, the median fre-
quency of CD56dim NK cells was significantly lower
in SF than PB in patients with antibiotic-responsive
arthritis (P= 0.02). However in patients with antibiotic-
refractory arthritis, the median frequency of these cells
was similar in SF and PB. Consequently, the frequency
of CD56dim NK cells in SF tended to be greater in pa-
tients with refractory arthritis than in those with respon-
sive arthritis (median value, 28% versus 17%, P =0.1).
Since CD56bright NK cells may differentiate into
CD56dim NK cells over time, the frequencies of these
subsets in SF in patients with antibiotic-refractory arth-
ritis were assessed according to the duration of arthritis
after the start of antibiotics. Only one patient with
refractory arthritis was evaluated prior to antibiotic the-
rapy, the time point when most patients with responsive
arthritis were seen, and the percentage of CD56bright
NK cells in that patient (0.6%) was very low. In addition,
five other patients were seen prior to the completion of
oral and IV antibiotic therapy (≤3 months after the initi-
ation of antibiotics) when some live spirochetes may
have been present, and nine were evaluated after the
completion of antibiotics (>3 months after the start of
antibiotics) when few, if any, live spirochetes remained.
Among the six patients with refractory arthritis who
were seen early in the course of the arthritis prior to the
completion of antibiotics (Figure 1d), the frequencies of
CD56bright NK cells tended to be less in those with re-
fractory arthritis than in those with responsive arthritis
(P =0.08), whereas the frequencies of CD56dim NK cells
were slightly greater in the refractory group. Similarly,
among the nine patients in the refractory group who
were seen late in the course of the arthritis after the
Table 1 Clinical characteristics of the twenty-three patients with Lyme arthritis and of four healthy control subjects*
Responsive Refractory P value
N=8** N=15**
Age, years 44 (17-53) 29 (12-78) 0.2
No. male/female 5/3 8/7 0.6
Duration of arthritis (months)
Before treatment 0.1 (0.1-1) 1 (0.1-6) 0.06
From start of antibiotics to sample date 0 (0-3) 4 (0-18) 0.001
From start of antibiotics to resolution of arthritis 3 (1.5-3) 10 (4-20) 0.0001
Serum findings on the sample date
Positive serologic result for B. burgdorferi
antibodies by ELISA and Western blotting 8 15 1.0
Joint fluid findings on the sample date
Total white cell count/mm
3 25,750 12,150 0.01
(13,833-60,000) (5,694-46,250)
% polymorphonuclear leukocytes 79 (28-91) 88 (16-98) 0.35
Total mononuclear cells/mm3 1,600 1,500 0.69
(400-6,500) (320-6,300)
No. PCR+/PCR- for B. burgdorferi DNA 8/0 5/10 0.002
*The four healthy control subjects had a median age of 36 (range, 28 to 42; three were women and one was a man. None had a positive serologic test result
for B. burgdorferi antibodies.
**All values are given as median (range) unless otherwise noted. ELISA, enzyme-linked immunosorbent assay.
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Figure 1 (See legend on next page.)
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tended to be less frequent than CD56dim NK cells
(P=0.08) (Figure 1d). Thus, regardless of when the sam-
ple was obtained, CD56dim NK cells were often pre-
dominant in the SF of patients with antibiotic-refractory
arthritis and the frequencies of CD56bright NK cells were
usually lower.
Since age and sex may influence the frequencies of NK
cells, the patients with antibiotic-responsive or antibiotic-
refractory arthritis were each stratified into two groups
according to age (those above or below the median value)
and sex (men or women). However, no significant dif-
ferences were noted in cell frequencies according to these
variables (data not shown).
Receptor expression of NK cell subsets
The expression of activation or inhibitory receptors was
assessed on CD56bright NK cells and CD56dim NK cells
in PB and SF from four or five patients each with re-
sponsive or refractory arthritis in whom enough cells
were available. As with the larger group of 23 patients,
the smaller group with antibiotic-responsive arthritis
were evaluated prior to or soon after the start of anti-
biotic therapy, and those with antibiotic-refractory arth-
ritis were seen at the completion of oral or IV antibiotic
therapy.
In both patient groups, high frequencies of CD56bright
and CD56dim NK cells in PB and SF expressed the acti-
vating receptor NKG2D and the chaperone molecule
CD94, which can pair with either activating or inhibiting
receptors (Figures 2a and b). In contrast, low frequencies
of CD56bright NK cells in PB and SF of both patient
groups expressed the inhibitory KIRs, which repress the
activity of NK cells (Figure 2c). However, the frequencies
of CD56dim NK cells that expressed KIR receptors were
significantly lower in SF compared with PB of both pa-
tients with responsive arthritis (P=0.04) and in those with
refractory arthritis (P= 0.03), suggesting that CD56dim
NK cells were less inhibited in SF than PB.
Expression of the FcγRIII receptor (CD16), which is
associated with antibody-dependent cellular cytotoxicity
(ADCC), is usually low or negligible on CD56bright NK
cells, but high on CD56dim NK cells, which typically
serve a cytotoxic function [19]. Here, this usual pattern
of CD16 expression was observed in PB from patients
with antibiotic-responsive arthritis (Figure 2d). However,
in both patient groups, CD16 expression on CD56dim
NK cells was significantly lower in SF than PB (P= 0.03).
Moreover, in patients with refractory arthritis, the usual
pattern of CD16 expression tended to be reversed in SF.
At that site, the refractory group tended to have higher
expression of CD16 on CD56bright NK cells (median
value =24%) compared with responsive patients (median
value =8%), whereas CD16 expression in CD56dim NK
cells was relatively low in the SF of both patient groups.
Thus, the low expression of CD16 on CD56dim NK cells
in SF suggested that these cells were not serving a cyto-
toxic function in SF in patients with responsive or re-
fractory Lyme arthritis.
Cytokine profile of B. burgdorferi-stimulated NK cells
Following stimulation with B. burgdorferi for 24 h, intra-
cellular cytokine production by NK cells was determined
in the SF of six patients with antibiotic-responsive arth-
ritis and seven patients with antibiotic-refractory arth-
ritis in whom enough cells were available. In these
patients, the timing of when the samples were obtained
was representative of the larger group of 23 patients.
The frequency of CD56bright NK cells that produced
IFN-γ tended to be higher in the refractory group than in
the responsive group (median 49% versus 21%, P=0. 1)
(Figure 3), and the frequencies of CD56dim NK cells that
produced this cytokine were also substantial in both the
responsive and refractory groups (approximately 20%),
suggesting that both cell types were often polarized to a
Th1 phenotype. In addition, in both patient groups, ap-
proximately 5% of CD56bright NK cells produced TNF-α,
but only a few CD56dim NK cells produced this cytokine.
A few patients in the refractory group had low percen-
tages of IL-4 staining cells, but in most patients, such cells
were not detectable. Thus, in patients with Lyme arthritis,
both CD56bright and CD56dim NK cells appear to secrete
primarily the Th1 cytokine IFN-γ, and in patients
with antibiotic-refractory arthritis, both CD56bright and
CD56dim NK cells continue to do so in the post-
antibiotic period.
(See figure on previous page.)
Figure 1 Frequencies of various immune cell subsets in patients with antibiotic-responsive or antibiotic-refractory Lyme arthritis.
(a) Representative dot plots of peripheral blood (PB) from one patient showing the gating strategy for the various lymphocyte populations.
(b and c) Enumeration of various immune cell subsets of matched PB and synovial fluid (SF) samples from eight antibiotic-responsive (Resp) and
fifteen antibiotic-refractory (Ref) patients, and for comparison four healthy control (HC) subjects. (d) Frequencies of cells in the SF of patients with
antibiotic-refractory arthritis were categorized based upon whether the sample was obtained early (≤3 months, N =6) or late (>3 months, N=9)
after the start of antibiotics. The graph on the left shows the percentages of CD56bright and CD56dim natural killer (NK) cells in refractory patients
whose samples were collected early in the course of their arthritis (≤3 months) compared with those from responsive patients. The graph on the
right compares the frequencies of CD56bright and CD56dim NK cells in refractory patients whose samples were obtained >3 months after the
start of antibiotics. Symbols indicate individual subjects, horizontal bars represent the median of each group and significant differences are
denoted. Statistical analyses were performed by using the Mann-Whitney test.
Katchar et al. Arthritis Research & Therapy 2013, 15:R183 Page 6 of 11
http://arthritis-research.com/content/15/6/R183Frequencies of invariant NKT cells
The frequencies of iNKT cells (CD3+CD56+Vα24+)
were determined in all 23 patients with antibiotic-respon-
sive or antibiotic-refractory arthritis, and in healthy con-
trol subjects. The gating strategy used to identify these
cells is shown in Figure 4a. Compared with healthy sub-
jects, the median frequencies of iNKTcells were increased
in PB in both patient groups (median values, 0.5% versus
approximately 3%) (Figure 4b). In SF, the frequencies of
iNKT in patients with antibiotic-responsive arthritis were
similar to that in PB. However, in patients with antibiotic-
refractory arthritis, iNKT cells were usually undetectable
in SF. Overall, seven of eight patients with responsive
arthritis had detectable iNKT cells in SF compared with
only four of fifteen patients with refractory arthritis
(P=0. 00 3) .
When the frequencies of iNKT cells in patients with
refractory arthritis were stratified according to when the
cells were obtained, similar frequencies were found in
patients who were seen prior to the completion of anti-
biotics (≤3 months, N =6) and in those seen after the
completion of antibiotics (>3 months, N =9) (Figure 4c).
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Figure 2 Frequencies of CD56bright and CD56dim NK cells that express the receptors NKG2D, CD94, KIRs (KIR3DL1 and KIR2DL2/2DL3)
or CD16. (a-b) Peripheral blood (PB) and synovial fluid (SF) samples from four to five patients with antibiotic-responsive arthritis and four to five
patients with antibiotic-refractory arthritis were analyzed for expression of NKG2D (a); CD94 (b); killer immunoglobulin-like receptors (KIRs) (c);o r
CD16 (d). For three of the five responsive patients, PB and SF samples were matched, and all PB and SF samples from refractory patients were
matched. Symbols indicate individual subjects, horizontal bars represent the median of each group and significant differences are denoted.
Statistical analyses were performed by using the Mann-Whitney test.
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and sex did not show significant differences (data not
shown). Because iNKT cells were often absent in SF in
the refractory group, the cytokine profiles of these cells
were not assessed.
Discussion
In this study, we compared NK and iNKT cell frequencies
and phenotypes in PB and SF in patients with antibiotic-
responsive or antibiotic-refractory arthritis. In other forms
of chronic inflammatory arthritis, it has been necessary to
compare findings in patients to those in patients with an-
other disease or healthy control subjects. However, one
can only obtain PB and not SF from healthy subjects. In
Lyme arthritis, in which the arthritis is often localized to
one knee, the frequencies and phenotypes of immune cells
in PB have often been similar in patients and healthy con-
trol subjects [14,15], as was the case here. Instead, the
IFN
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Figure 3 Frequencies of SF CD56bright and CD56dim NK cells that secrete IFNγ, TNFα and IL-4 in patients with antibiotic-responsive or
antibiotic-refractory arthritis. Synovial fluid (SF) cells from six antibiotic-responsive (Resp) and seven antibiotic-refractory (Ref) patients were
stimulated with B. burgdorferi at a multiplicity of infection (MOI) of 25:1 for 24 h. For the last 6 h, GolgiStop was added and the presence of IFNγ,
TNFα and IL-4 was measured by intracytoplasmic staining and flow cytometry. Symbols indicate individual subjects and horizontal bars represent
the median of each group. Statistical analyses were performed by using the Mann-Whitney test.
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Figure 4 Frequencies of Vα24+ (invariant) NKT cells in patients with antibiotic-responsive or antibiotic-refractory arthritis.
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invariant natural killer T cells (iNKT) in patient samples. (b) Frequencies of iNKT cells in matched PB and synovial fluid (SF) samples from eight
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late (>3 months, N=9) after the start of antibiotics. Symbols indicate individual subjects, horizontal bars represent the median of each group
and significant differences are denoted. Statistical analyses were performed by using the Mann-Whitney test.
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from antibiotic-responsive patients during infection
versus SF obtained from antibiotic-refractory patients
during the post-antibiotic period when excessive inflam-
mation, immune dysregulation, and infection-induced
a u t o i m m u n i t ya r et h o u g h tt op l a yap a t h o g e n e t i cr o l ei n
the illness [15,16].
In the current study, patients with antibiotic-responsive
arthritis, who were evaluated during active infection, had
high frequencies of CD56bright NK cells in SF, the site of
inflammation. In addition, a high percentage of the cells
expressed the activation receptor NKG2D and the
chaperone CD94, whereas a low percentage expressed in-
hibitory KIR receptors. Furthermore, a high percentage of
the cells produced IFN-γ, a characteristic Th1-associated
cytokine that is prominent during infection [34-36]. This
is the typical phenotype of CD56bright NK cells at sites of
inflammation [18], and suggests that in Lyme disease,
these cells still have a role in control of the infection in
joints late in the illness.
In comparison, patients with antibiotic-refractory
arthritis, who were usually seen near or at the conclu-
sion of antibiotic therapy when few, if any, live spiro-
chetes remained [10], had a similar activated phenotype
of CD56bright cells in SF as in patients with antibiotic-
responsive arthritis, but the frequencies of these cells
were significantly less. Instead, patients with antibiotic-
refractory arthritis tended to have more CD56dim NK
cells in SF. Since CD56bright NK cells may evolve into
CD56dim cells as they mature, we considered whether
this finding could be explained simply by the fact that
the cells in antibiotic-refractory patients were usually
obtained during the post-antibiotic period. However,
even in refractory patients in whom the cells were col-
lected earlier in the course of the arthritis, the percen-
tages of CD56bright cells were less and the numbers of
NKdim cells proportionally more than in patients with
responsive arthritis, suggesting that the differences
between the two patient groups were not simply a func-
tion of time.
Rather than the typical phenotype of CD56dim cells,
these cells in both responsive and refractory patients often
produced IFN-γ, and had low expression of CD16 recep-
tors, suggesting that the cells were not serving their usual
cytotoxic function [23]. Rather, the frequencies of IFN-γ-
producing CD56bright and CD56dim remained high, even
after spirochetal killing. We have previously shown that
patients with antibiotic-refractory arthritis have signi-
ficantly higher levels of proinflammatory cytokines and
chemokines in SF, particularly IFN-γ and the IFN-
inducible chemokines CXCL9 and CXCL10, than patients
with antibiotic-responsive arthritis [10,37]. Moreover, this
highly inflammatory milieu is associated with a persistent
imbalance of the CD4+ effector T/regulatory T cell ratio
in SF weighted toward effector T cells, such that the
higher the ratio the longer the post-antibiotic duration of
arthritis [15]. Thus, in refractory patients, IFN-γ-produ-
cing CD56bright and CD56dim NK cells may contribute
to the excessive inflammation and immune dysregula-
tion that is characteristic of antibiotic-refractory Lyme
arthritis.
As with NK cells, patients with antibiotic-responsive
arthritis had higher frequencies of iNKT cells in SF than
PB, but these cells were often absent in SF in patients with
antibiotic-refractory arthritis. The first demonstration of a
glycoplipid antigen from a human pathogen presented by
CD1d molecules to iNKT cells was B. burgdorferi mono-
galactosyl diacylglycerol (BbGLII) [25], one of the two
B. burgdorferi glycolipids [38,39]. Furthermore, in mice,
which only express CD1d molecules, iNKT cells were
shown to be important for control of early infection
[25-27]. In humans, skin explants from healthy control
subjects had constitutive expression of CD1a, but low
expression of CD1b and CD1c molecules [28]. When the
explants were cultured with B. burgdorferi,C D 1 ba n d
CD1c expression increased substantially on myeloid den-
dritic cells. Finally, both acylated cholesteryl galactoside
(BbGLI) and BbGLII induce robust antibody responses in
approximately one-third of patients with early infection
and in almost all patients with Lyme arthritis, including
those with refractory arthritis [39]. Thus, iNKT cells in SF
likely help B cells to produce antibodies to B. burgdorferi
glycolipids, which may aid in spirochetal killing. However,
the absence of these cells in SF in patients with refractory
arthritis may contribute to the inability of these patients
to downmodulate their immune response after spirochetal
clearance. Furthermore, the low level or lack of these cells
in SF suggests that self lipids do not play a role in auto-
immunity in the post-antibiotic period in patients with
antibiotic-refractory arthritis.
In autoimmune diseases, it has been suggested that
CD56bright NK cells may either exacerbate or regulate
immune responses [40]. In rheumatoid arthritis (RA),
CD56bright NK cells are greatly enriched in SF or synovial
tissue, and may engage with monocytes in a reciprocal
program of activation [41]. In comparison, the frequency
of these cells in PB may be less than in healthy control
subjects [42], presumably because the cells have migrated
to inflamed joints. In patients with multiple sclerosis, cli-
nical remission after treatment with IFN-β and daclimu-
mab was associated with an expansion of CD56bright NK
cells in PB [43], but this may result from the exiting of
these cells from sites of inflammation.
In RA, it has also been questioned whether iNKT cells
are contributors or modulators of inflammation [40]. In
RA patients, clinical improvement in response to rituxi-
mab was associated with increased numbers of iNKT
cells in PB [44], but again, this could be caused by the
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collagen-induced arthritis, iNKT cell secretion of IFN-γ
suppressed Th17 cell differentiation; it induced regulatory
T cells, and it caused apoptosis of autoreactive T cells
[45]. Similarly, in KBxN mice, iNKT cells activated by
α-galactosylceramide (α-GalCer) suppressed glucose-6-
phosphate isomerase (GPI) peptide-induced arthritis by
suppression of GPI-specific CD4+ T cells [46]. In future
experiments, it will be important to explore both the
effector and immunoregulatory potential of these cells in
patients with Lyme arthritis.
It has been reported that determination of NK cell
numbers, identified by CD57, a marker for replicative
senescence, may provide evidence for activity of disease
and response to therapy in patients with post-Lyme
disease pain, neurocognitive and fatigue symptoms [47].
However, using both CD56 and CD57 staining, others
found that NK cell counts were similar in patients with
post-Lyme symptoms and in healthy control subjects
[48]. Although we noted differences in the frequencies
of NK cell subsets in SF compared with PB, NK cell
numbers were similar in PB in patients with either
responsive or refractory Lyme arthritis and in healthy
control subjects.
Conclusions
In patients with antibiotic-responsive arthritis, who were
seen during active infection, the high percentages of ac-
tivated, IFN-γ-producing CD56bright NK cells in SF and
the presence of iNKT cells suggest that these cells still
have a role in spirochetal killing late in the illness. In pa-
tients with antibiotic-refractory arthritis, the frequencies
of IFN-γ-producing CD56bright and CD56dim NK cells
in SF remained high, even after spirochetal killing, sug-
gesting that these cells contribute to excessive inflamma-
tion and immune dysregulation in joints. Additionally,
the lack of iNKT cells in the SF of refractory patients
suggests that their absence may further contribute to the
immune dysregulation experienced by these patients.
Overall, quantitative rather than qualitative differences
in NK and iNKT cell populations appear to contribute to
an antibiotic-refractory arthritis outcome.
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